0001567619-18-007783.txt : 20181212
0001567619-18-007783.hdr.sgml : 20181212
20181212171249
ACCESSION NUMBER: 0001567619-18-007783
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181210
FILED AS OF DATE: 20181212
DATE AS OF CHANGE: 20181212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bilenker Joshua H.
CENTRAL INDEX KEY: 0001612312
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36562
FILM NUMBER: 181231495
MAIL ADDRESS:
STREET 1: C/O LOXO ONCOLOGY, INC.
STREET 2: ONE LANDMARK SQUARE, SUITE 1122
CITY: STAMFORD
STATE: CT
ZIP: 06901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Loxo Oncology, Inc.
CENTRAL INDEX KEY: 0001581720
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462996673
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06901
BUSINESS PHONE: 203-653-3880
MAIL ADDRESS:
STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06901
4
1
doc1.xml
FORM 4
X0306
4
2018-12-10
0
0001581720
Loxo Oncology, Inc.
LOXO
0001612312
Bilenker Joshua H.
C/O LOXO ONCOLOGY, INC.
ONE LANDMARK SQUARE, SUITE 1122
STAMFORD
CT
06901
1
1
0
0
President & CEO
Common Stock
2018-12-10
4
M
0
10000
13.67
A
174407
D
Common Stock
2018-12-10
4
S
0
969
130.58
D
173438
D
Common Stock
2018-12-10
4
S
0
2001
132.09
D
171437
D
Common Stock
2018-12-10
4
S
0
2104
133.00
D
169333
D
Common Stock
2018-12-10
4
S
0
2049
134.31
D
167284
D
Common Stock
2018-12-10
4
S
0
2377
135.04
D
164907
D
Common Stock
2018-12-10
4
S
0
400
136.48
D
164507
D
Common Stock
2018-12-10
4
S
0
100
137.39
D
164407
D
Common Stock
2018-12-11
4
M
0
10000
13.67
A
174407
D
Common Stock
2018-12-11
4
S
0
647
134.63
D
173760
D
Common Stock
2018-12-11
4
S
0
1153
135.76
D
172607
D
Common Stock
2018-12-11
4
S
0
3393
136.79
D
169214
D
Common Stock
2018-12-11
4
S
0
2407
137.63
D
166807
D
Common Stock
2018-12-11
4
S
0
1100
139.05
D
165707
D
Common Stock
2018-12-11
4
S
0
1200
140.15
D
164507
D
Common Stock
2018-12-11
4
S
0
100
140.61
D
164407
D
Common Stock
30000
I
By Joshua H. Bilenker, ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018
Employee Stock Option (Right to Buy)
13.67
2018-12-10
4
M
0
10000
0
D
2024-12-18
Common Stock
10000
328514
D
Employee Stock Option (Right to Buy)
13.67
2018-12-11
4
M
0
10000
0
D
2024-12-18
Common Stock
10000
318514
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
Represents the aggregate of sales effected on the same day at different prices.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.14 to $131.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.48 to $132.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.56 to $133.54 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.91 to $134.83 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.91 to $135.41 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.09 to $136.86 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.28 to $135.19 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.30 to $136.28 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.31 to $137.30 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.32 to $138.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.53 to $139.40 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.59 to $140.57 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
/s/Jennifer Burstein, by power of attorney
2018-12-12